Boston, MA -- (SBWIRE) -- 07/27/2017 -- According to the recently published report 'Histone Lysine N Methyltransferase EHMT2 - Pipeline Review, H1 2017'; Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) pipeline Target constitutes close to 6 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes.

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Euchromatic histone-lysine N-methyltransferase 2 (EHMT2) is a histone methyltransferase encoded by the EHMT2 gene. It mediates monomethylation of 'Lys-56' of histone H3 (H3K56me1) in G1 phase, leading to promote interaction between histone H3 and PCNA and regulating DNA replication. It weakly methylates 'Lys-27' of histone H3 (H3K27me). It is required for DNA methylation.

Get More Details on this Report and a Full Table of Contents at Histone Lysine N Methyltransferase EHMT2 - Pipeline Review, H1 2017

The report 'Histone Lysine N Methyltransferase EHMT2 - Pipeline Review, H1 2017' outlays comprehensive information on the Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Gastrointestinal which include indications Malaria, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colon Cancer, Hepatocellular Carcinoma, Leukemias, Liver Fibrosis and Lymphoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43)

-The report reviews Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects

-The report assesses Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H1 2017
-Histone Lysine N Methyltransferase EHMT2 - Pipeline Review, H2 2016
-Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2016
-Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2017
-Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H1 2017